Kymera Therapeutics partners with Gilead Sciences to develop cancer treatments, positive.

From Financial Modeling Prep.: 2025-06-25 18:11:00

Kymera Therapeutics (NASDAQ: KYMR) is a biopharmaceutical company specializing in targeted protein degradation to treat diseases. Their collaboration with Gilead Sciences focuses on developing molecular glue degraders for cancer treatment, showcasing their potential in the oncology market.

Analyst Kelly Shi set a $64 price target for Kymera, anticipating a 38.5% increase from the current price of $46.21. The partnership with Gilead Sciences, valued at up to $750 million, aims to create a novel cancer treatment targeting CDK2, positioning Kymera for growth in oncology.

The collaboration between Gilead and Kymera focuses on developing molecular glue degraders, a new class of drugs that selectively remove disease-causing proteins like CDK2 from cancer cells. This innovative approach offers promising opportunities in cancer research, particularly for breast cancer and solid tumors.

Kymera’s stock is currently trading at $46.68, with fluctuations between $44.62 and $46.79 during the trading day. With a market capitalization of $3.04 billion, Kymera is well-equipped to leverage its innovative therapies and strategic partnerships for growth in the biopharmaceutical industry.



Read more at Financial Modeling Prep.:: Kymera Therapeutics (NASDAQ:KYMR) Partners with Gi…